Since ONC212 showed notable pre-clinical efficacy against pancreatic cancer, both as a single agent as well as in combination with an IGF1-R inhibitor, we wanted to test its potential in combination with FDA-approved drugs for pancreatic cancer. Here, IGF1R is linked to familial pancreatic carcinoma.